生物制剂与抗癌药联合动脉导管灌注治疗中晚期肺癌临床应用

Transcatheter arterial chemoembolization combined with biologic production for the middle-or late-stage pulmonary carcinoma

目的应用生物制剂与抗癌药联合支气管动脉导管灌注治疗中晚期肺癌，探讨其临床价值。方法中晚期肺癌（转移瘤7例）21例，分别经支气管动脉灌注，支气管动脉、内乳动脉的部分血管栓塞，同时经支气管动脉或肺动脉灌注淋巴激活因子杀伤（LAK）细胞（10～15亿）和高聚金葡素（3000-6000U）等免疫生物剂。结果21例肺内病灶均见不同程度的缩小，数目减少，有效率达到100％。其中3例肺内肿块完全消失，5例肺肿块显示明显缩小，并行手术切除，6例肺转移灶明显缩小。随访1．5年，其生存率100％，两年以上生存率为85．7％（18／21），与化疗相关的毒副作用明显减轻。结论生物制剂与抗癌药联合支气管动脉导管灌注治疗中晚期肺癌，有利于提高疗效和生存质量。

Objective To explore the therapeutic effect of bronchial arterial infusion （BAI） and bronchial arterial embolus （BAE） combined with biologic production for the middle- or late-stage lung carcinoma. Methods The middle- or latestage lung cancer （7 cases with metastasis lung cancer） was performed by BAI and BAE in 21 patients or intrathoracic artery embolus of some patients. The bronchial artery or pulmonary artery infusion of LAK （about 100-- 150 million）, and highly agglutinated staphylococcin at a dose of 3000-6000 U were taken. Results The size of lung tumor was reduced in 21 patients, the total effectiveness rate was 100%. The tumors disappeared in 3 cases, pulmonary metastasis tumor obviously decreased in 6 cases. The reduced lesions of 5 patients were operated. The survival rate of 1.5 years was 100%, of 2 years was 85.7% （18/21）. The slde-effect of long-term chemotherapy was obviously lightening. Conclusion It is useful to enhance the therapy effect and improve the survival rate or the quality of life by artery embolus, chemotherapy, and biologic production of conjugation infusion in middle- or late-stage pulmonary carcinoma.